Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
Identifieur interne : 001E72 ( PubMed/Curation ); précédent : 001E71; suivant : 001E73Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
Auteurs : S Rachel Skinner [Australie] ; Cosette M. Wheeler [États-Unis] ; Barbara Romanowski [Canada] ; Xavier Castellsagué [Espagne] ; Eduardo Lazcano-Ponce [Mexique] ; M Rowena Del Rosario-Raymundo [Philippines] ; Carlos Vallejos [Pérou] ; Galina Minkina [Russie] ; Daniel Pereira Da Silva [Portugal] ; Shelly Mcneil [Canada] ; Vera Prilepskaya [Russie] ; Irina Gogotadze [Russie] ; Deborah Money [Canada] ; Suzanne M. Garland [Australie] ; Viktor Romanenko [Russie] ; Diane M. Harper [États-Unis] ; Myron J. Levin [États-Unis] ; Archana Chatterjee [États-Unis] ; Brecht Geeraerts [Belgique] ; Frank Struyf [Belgique] ; Gary Dubin [États-Unis] ; Marie-Cécile Bozonnat [France] ; Dominique Rosillon [Belgique] ; Laurence Baril [Belgique]Source :
- International journal of cancer [ 1097-0215 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Alphapapillomavirus (), Détection précoce de cancer, Essais cliniques de phase III comme sujet, Femelle, Humains, Infections à papillomavirus (), Infections à papillomavirus (virologie), Néoplasie intraépithéliale cervicale (anatomopathologie), Néoplasie intraépithéliale cervicale (épidémiologie), Néoplasie intraépithéliale cervicale (étiologie), Risque, Surveillance de la santé publique, Tumeurs du col de l'utérus (anatomopathologie), Tumeurs du col de l'utérus (épidémiologie), Tumeurs du col de l'utérus (étiologie), Vaccins contre les papillomavirus (immunologie), Études de suivi, Évolution de la maladie.
- MESH :
- anatomopathologie : Néoplasie intraépithéliale cervicale, Tumeurs du col de l'utérus.
- immunologie : Vaccins contre les papillomavirus.
- virologie : Infections à papillomavirus.
- épidémiologie : Néoplasie intraépithéliale cervicale, Tumeurs du col de l'utérus.
- étiologie : Néoplasie intraépithéliale cervicale, Tumeurs du col de l'utérus.
- Adulte, Adulte d'âge moyen, Alphapapillomavirus, Détection précoce de cancer, Essais cliniques de phase III comme sujet, Femelle, Humains, Infections à papillomavirus, Risque, Surveillance de la santé publique, Études de suivi, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Alphapapillomavirus (classification), Cervical Intraepithelial Neoplasia (epidemiology), Cervical Intraepithelial Neoplasia (etiology), Cervical Intraepithelial Neoplasia (pathology), Clinical Trials, Phase III as Topic, Disease Progression, Early Detection of Cancer, Female, Follow-Up Studies, Humans, Middle Aged, Papillomavirus Infections (complications), Papillomavirus Infections (prevention & control), Papillomavirus Infections (virology), Papillomavirus Vaccines (immunology), Public Health Surveillance, Risk, Uterine Cervical Neoplasms (epidemiology), Uterine Cervical Neoplasms (etiology), Uterine Cervical Neoplasms (pathology).
- MESH :
- chemical , immunology : Papillomavirus Vaccines.
- classification : Alphapapillomavirus.
- complications : Papillomavirus Infections.
- epidemiology : Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms.
- etiology : Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms.
- pathology : Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms.
- prevention & control : Papillomavirus Infections.
- virology : Papillomavirus Infections.
- Adult, Clinical Trials, Phase III as Topic, Disease Progression, Early Detection of Cancer, Female, Follow-Up Studies, Humans, Middle Aged, Public Health Surveillance, Risk.
Abstract
The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk of progression from cervical HPV infection to detectable cervical intraepithelial neoplasia (CIN). The risk of detecting CIN associated with the same HPV type as the reference infection was analysed using Kaplan-Meier and multivariable Cox models. Infections were categorised depending upon persistence as 6-month persistent infection (6MPI) or infection of any duration. The 4-year interim analysis included 2,838 women, of whom 1,073 (37.8%) experienced 2,615 infections of any duration and 708 (24.9%) experienced 1,130 6MPIs. Infection with oncogenic HPV types significantly increased the risk of detecting CIN grade 2 or greater (CIN2+) versus non-oncogenic types. For 6MPI, the highest risk was associated with HPV-33 (hazard ratio [HR]: 31.9 [8.3-122.2, p < 0.0001]). The next highest risk was with HPV-16 (21.1 [6.3-70.0], p < 0.0001). Similar findings were seen for infections of any duration. Significant risk was also observed for HPV-18, HPV-31, and HPV-45. Concomitant HPV infection or CIN grade 1 or greater associated with a different oncogenic HPV type increased risk. Most women (79.3%) with an HPV infection at baseline cleared detectable infections of any duration, and 69.9% cleared a 6MPI. The risk of progression of HPV infection to CIN2+ in women >25 years in this study was similar to that in women 15-25 years in PATRICIA.
DOI: 10.1002/ijc.29971
PubMed: 26685704
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E96
Links to Exploration step
pubmed:26685704Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.</title>
<author><name sortKey="Skinner, S Rachel" sort="Skinner, S Rachel" uniqKey="Skinner S" first="S Rachel" last="Skinner">S Rachel Skinner</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheeler, Cosette M" sort="Wheeler, Cosette M" uniqKey="Wheeler C" first="Cosette M" last="Wheeler">Cosette M. Wheeler</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romanowski, Barbara" sort="Romanowski, Barbara" uniqKey="Romanowski B" first="Barbara" last="Romanowski">Barbara Romanowski</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lazcano Ponce, Eduardo" sort="Lazcano Ponce, Eduardo" uniqKey="Lazcano Ponce E" first="Eduardo" last="Lazcano-Ponce">Eduardo Lazcano-Ponce</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute of Public Health, Cuernavaca, Mexico.</nlm:affiliation>
<country xml:lang="fr">Mexique</country>
<wicri:regionArea>National Institute of Public Health, Cuernavaca</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Del Rosario Raymundo, M Rowena" sort="Del Rosario Raymundo, M Rowena" uniqKey="Del Rosario Raymundo M" first="M Rowena" last="Del Rosario-Raymundo">M Rowena Del Rosario-Raymundo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines.</nlm:affiliation>
<country xml:lang="fr">Philippines</country>
<wicri:regionArea>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vallejos, Carlos" sort="Vallejos, Carlos" uniqKey="Vallejos C" first="Carlos" last="Vallejos">Carlos Vallejos</name>
<affiliation wicri:level="1"><nlm:affiliation>Division de Investigacion Oncosalud-AUNA, Lima, Peru.</nlm:affiliation>
<country xml:lang="fr">Pérou</country>
<wicri:regionArea>Division de Investigacion Oncosalud-AUNA, Lima</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Minkina, Galina" sort="Minkina, Galina" uniqKey="Minkina G" first="Galina" last="Minkina">Galina Minkina</name>
<affiliation wicri:level="1"><nlm:affiliation>City Clinical Hospital, Moscow, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Clinical Hospital, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pereira Da Silva, Daniel" sort="Pereira Da Silva, Daniel" uniqKey="Pereira Da Silva D" first="Daniel" last="Pereira Da Silva">Daniel Pereira Da Silva</name>
<affiliation wicri:level="1"><nlm:affiliation>Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcneil, Shelly" sort="Mcneil, Shelly" uniqKey="Mcneil S" first="Shelly" last="Mcneil">Shelly Mcneil</name>
<affiliation wicri:level="1"><nlm:affiliation>Canadian Center for Vaccinology, IWK Health Center and Capital Health, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Canadian Center for Vaccinology, IWK Health Center and Capital Health, Dalhousie University, Halifax, NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Prilepskaya, Vera" sort="Prilepskaya, Vera" uniqKey="Prilepskaya V" first="Vera" last="Prilepskaya">Vera Prilepskaya</name>
<affiliation wicri:level="1"><nlm:affiliation>Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gogotadze, Irina" sort="Gogotadze, Irina" uniqKey="Gogotadze I" first="Irina" last="Gogotadze">Irina Gogotadze</name>
<affiliation wicri:level="1"><nlm:affiliation>City Medical Center, St Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Medical Center, St Petersburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Money, Deborah" sort="Money, Deborah" uniqKey="Money D" first="Deborah" last="Money">Deborah Money</name>
<affiliation wicri:level="1"><nlm:affiliation>University of British Columbia, The Women's Health Research Institute, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia, The Women's Health Research Institute, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romanenko, Viktor" sort="Romanenko, Viktor" uniqKey="Romanenko V" first="Viktor" last="Romanenko">Viktor Romanenko</name>
<affiliation wicri:level="1"><nlm:affiliation>City Children's Hospital N40, Ekaterinburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Children's Hospital N40, Ekaterinburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Harper, Diane M" sort="Harper, Diane M" uniqKey="Harper D" first="Diane M" last="Harper">Diane M. Harper</name>
<affiliation wicri:level="1"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and University of Louisville School of Medicine, Louisville, KT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and University of Louisville School of Medicine, Louisville, KT</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Levin, Myron J" sort="Levin, Myron J" uniqKey="Levin M" first="Myron J" last="Levin">Myron J. Levin</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chatterjee, Archana" sort="Chatterjee, Archana" uniqKey="Chatterjee A" first="Archana" last="Chatterjee">Archana Chatterjee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Geeraerts, Brecht" sort="Geeraerts, Brecht" uniqKey="Geeraerts B" first="Brecht" last="Geeraerts">Brecht Geeraerts</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Struyf, Frank" sort="Struyf, Frank" uniqKey="Struyf F" first="Frank" last="Struyf">Frank Struyf</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dubin, Gary" sort="Dubin, Gary" uniqKey="Dubin G" first="Gary" last="Dubin">Gary Dubin</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, King of Prussia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>GSK Vaccines, King of Prussia, PA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bozonnat, Marie Cecile" sort="Bozonnat, Marie Cecile" uniqKey="Bozonnat M" first="Marie-Cécile" last="Bozonnat">Marie-Cécile Bozonnat</name>
<affiliation wicri:level="1"><nlm:affiliation>4Clinics, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>4Clinics, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosillon, Dominique" sort="Rosillon, Dominique" uniqKey="Rosillon D" first="Dominique" last="Rosillon">Dominique Rosillon</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baril, Laurence" sort="Baril, Laurence" uniqKey="Baril L" first="Laurence" last="Baril">Laurence Baril</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26685704</idno>
<idno type="pmid">26685704</idno>
<idno type="doi">10.1002/ijc.29971</idno>
<idno type="wicri:Area/PubMed/Corpus">001E96</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E96</idno>
<idno type="wicri:Area/PubMed/Curation">001E72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E72</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.</title>
<author><name sortKey="Skinner, S Rachel" sort="Skinner, S Rachel" uniqKey="Skinner S" first="S Rachel" last="Skinner">S Rachel Skinner</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheeler, Cosette M" sort="Wheeler, Cosette M" uniqKey="Wheeler C" first="Cosette M" last="Wheeler">Cosette M. Wheeler</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romanowski, Barbara" sort="Romanowski, Barbara" uniqKey="Romanowski B" first="Barbara" last="Romanowski">Barbara Romanowski</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lazcano Ponce, Eduardo" sort="Lazcano Ponce, Eduardo" uniqKey="Lazcano Ponce E" first="Eduardo" last="Lazcano-Ponce">Eduardo Lazcano-Ponce</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute of Public Health, Cuernavaca, Mexico.</nlm:affiliation>
<country xml:lang="fr">Mexique</country>
<wicri:regionArea>National Institute of Public Health, Cuernavaca</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Del Rosario Raymundo, M Rowena" sort="Del Rosario Raymundo, M Rowena" uniqKey="Del Rosario Raymundo M" first="M Rowena" last="Del Rosario-Raymundo">M Rowena Del Rosario-Raymundo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines.</nlm:affiliation>
<country xml:lang="fr">Philippines</country>
<wicri:regionArea>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vallejos, Carlos" sort="Vallejos, Carlos" uniqKey="Vallejos C" first="Carlos" last="Vallejos">Carlos Vallejos</name>
<affiliation wicri:level="1"><nlm:affiliation>Division de Investigacion Oncosalud-AUNA, Lima, Peru.</nlm:affiliation>
<country xml:lang="fr">Pérou</country>
<wicri:regionArea>Division de Investigacion Oncosalud-AUNA, Lima</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Minkina, Galina" sort="Minkina, Galina" uniqKey="Minkina G" first="Galina" last="Minkina">Galina Minkina</name>
<affiliation wicri:level="1"><nlm:affiliation>City Clinical Hospital, Moscow, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Clinical Hospital, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pereira Da Silva, Daniel" sort="Pereira Da Silva, Daniel" uniqKey="Pereira Da Silva D" first="Daniel" last="Pereira Da Silva">Daniel Pereira Da Silva</name>
<affiliation wicri:level="1"><nlm:affiliation>Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mcneil, Shelly" sort="Mcneil, Shelly" uniqKey="Mcneil S" first="Shelly" last="Mcneil">Shelly Mcneil</name>
<affiliation wicri:level="1"><nlm:affiliation>Canadian Center for Vaccinology, IWK Health Center and Capital Health, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Canadian Center for Vaccinology, IWK Health Center and Capital Health, Dalhousie University, Halifax, NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Prilepskaya, Vera" sort="Prilepskaya, Vera" uniqKey="Prilepskaya V" first="Vera" last="Prilepskaya">Vera Prilepskaya</name>
<affiliation wicri:level="1"><nlm:affiliation>Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gogotadze, Irina" sort="Gogotadze, Irina" uniqKey="Gogotadze I" first="Irina" last="Gogotadze">Irina Gogotadze</name>
<affiliation wicri:level="1"><nlm:affiliation>City Medical Center, St Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Medical Center, St Petersburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Money, Deborah" sort="Money, Deborah" uniqKey="Money D" first="Deborah" last="Money">Deborah Money</name>
<affiliation wicri:level="1"><nlm:affiliation>University of British Columbia, The Women's Health Research Institute, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia, The Women's Health Research Institute, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romanenko, Viktor" sort="Romanenko, Viktor" uniqKey="Romanenko V" first="Viktor" last="Romanenko">Viktor Romanenko</name>
<affiliation wicri:level="1"><nlm:affiliation>City Children's Hospital N40, Ekaterinburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>City Children's Hospital N40, Ekaterinburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Harper, Diane M" sort="Harper, Diane M" uniqKey="Harper D" first="Diane M" last="Harper">Diane M. Harper</name>
<affiliation wicri:level="1"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and University of Louisville School of Medicine, Louisville, KT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and University of Louisville School of Medicine, Louisville, KT</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Levin, Myron J" sort="Levin, Myron J" uniqKey="Levin M" first="Myron J" last="Levin">Myron J. Levin</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chatterjee, Archana" sort="Chatterjee, Archana" uniqKey="Chatterjee A" first="Archana" last="Chatterjee">Archana Chatterjee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Geeraerts, Brecht" sort="Geeraerts, Brecht" uniqKey="Geeraerts B" first="Brecht" last="Geeraerts">Brecht Geeraerts</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Struyf, Frank" sort="Struyf, Frank" uniqKey="Struyf F" first="Frank" last="Struyf">Frank Struyf</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dubin, Gary" sort="Dubin, Gary" uniqKey="Dubin G" first="Gary" last="Dubin">Gary Dubin</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, King of Prussia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>GSK Vaccines, King of Prussia, PA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bozonnat, Marie Cecile" sort="Bozonnat, Marie Cecile" uniqKey="Bozonnat M" first="Marie-Cécile" last="Bozonnat">Marie-Cécile Bozonnat</name>
<affiliation wicri:level="1"><nlm:affiliation>4Clinics, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>4Clinics, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosillon, Dominique" sort="Rosillon, Dominique" uniqKey="Rosillon D" first="Dominique" last="Rosillon">Dominique Rosillon</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baril, Laurence" sort="Baril, Laurence" uniqKey="Baril L" first="Laurence" last="Baril">Laurence Baril</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of cancer</title>
<idno type="eISSN">1097-0215</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Alphapapillomavirus (classification)</term>
<term>Cervical Intraepithelial Neoplasia (epidemiology)</term>
<term>Cervical Intraepithelial Neoplasia (etiology)</term>
<term>Cervical Intraepithelial Neoplasia (pathology)</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Disease Progression</term>
<term>Early Detection of Cancer</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Papillomavirus Infections (complications)</term>
<term>Papillomavirus Infections (prevention & control)</term>
<term>Papillomavirus Infections (virology)</term>
<term>Papillomavirus Vaccines (immunology)</term>
<term>Public Health Surveillance</term>
<term>Risk</term>
<term>Uterine Cervical Neoplasms (epidemiology)</term>
<term>Uterine Cervical Neoplasms (etiology)</term>
<term>Uterine Cervical Neoplasms (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Alphapapillomavirus ()</term>
<term>Détection précoce de cancer</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus ()</term>
<term>Infections à papillomavirus (virologie)</term>
<term>Néoplasie intraépithéliale cervicale (anatomopathologie)</term>
<term>Néoplasie intraépithéliale cervicale (épidémiologie)</term>
<term>Néoplasie intraépithéliale cervicale (étiologie)</term>
<term>Risque</term>
<term>Surveillance de la santé publique</term>
<term>Tumeurs du col de l'utérus (anatomopathologie)</term>
<term>Tumeurs du col de l'utérus (épidémiologie)</term>
<term>Tumeurs du col de l'utérus (étiologie)</term>
<term>Vaccins contre les papillomavirus (immunologie)</term>
<term>Études de suivi</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Papillomavirus Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Néoplasie intraépithéliale cervicale</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Alphapapillomavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Papillomavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cervical Intraepithelial Neoplasia</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cervical Intraepithelial Neoplasia</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins contre les papillomavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cervical Intraepithelial Neoplasia</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Papillomavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à papillomavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Papillomavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Néoplasie intraépithéliale cervicale</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Néoplasie intraépithéliale cervicale</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Disease Progression</term>
<term>Early Detection of Cancer</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Public Health Surveillance</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Alphapapillomavirus</term>
<term>Détection précoce de cancer</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus</term>
<term>Risque</term>
<term>Surveillance de la santé publique</term>
<term>Études de suivi</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk of progression from cervical HPV infection to detectable cervical intraepithelial neoplasia (CIN). The risk of detecting CIN associated with the same HPV type as the reference infection was analysed using Kaplan-Meier and multivariable Cox models. Infections were categorised depending upon persistence as 6-month persistent infection (6MPI) or infection of any duration. The 4-year interim analysis included 2,838 women, of whom 1,073 (37.8%) experienced 2,615 infections of any duration and 708 (24.9%) experienced 1,130 6MPIs. Infection with oncogenic HPV types significantly increased the risk of detecting CIN grade 2 or greater (CIN2+) versus non-oncogenic types. For 6MPI, the highest risk was associated with HPV-33 (hazard ratio [HR]: 31.9 [8.3-122.2, p < 0.0001]). The next highest risk was with HPV-16 (21.1 [6.3-70.0], p < 0.0001). Similar findings were seen for infections of any duration. Significant risk was also observed for HPV-18, HPV-31, and HPV-45. Concomitant HPV infection or CIN grade 1 or greater associated with a different oncogenic HPV type increased risk. Most women (79.3%) with an HPV infection at baseline cleared detectable infections of any duration, and 69.9% cleared a 6MPI. The risk of progression of HPV infection to CIN2+ in women >25 years in this study was similar to that in women 15-25 years in PATRICIA.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26685704</PMID>
<DateCreated><Year>2016</Year>
<Month>03</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>08</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-0215</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>138</Volume>
<Issue>10</Issue>
<PubDate><Year>2016</Year>
<Month>May</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>International journal of cancer</Title>
<ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.</ArticleTitle>
<Pagination><MedlinePgn>2428-38</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.29971</ELocationID>
<Abstract><AbstractText>The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk of progression from cervical HPV infection to detectable cervical intraepithelial neoplasia (CIN). The risk of detecting CIN associated with the same HPV type as the reference infection was analysed using Kaplan-Meier and multivariable Cox models. Infections were categorised depending upon persistence as 6-month persistent infection (6MPI) or infection of any duration. The 4-year interim analysis included 2,838 women, of whom 1,073 (37.8%) experienced 2,615 infections of any duration and 708 (24.9%) experienced 1,130 6MPIs. Infection with oncogenic HPV types significantly increased the risk of detecting CIN grade 2 or greater (CIN2+) versus non-oncogenic types. For 6MPI, the highest risk was associated with HPV-33 (hazard ratio [HR]: 31.9 [8.3-122.2, p < 0.0001]). The next highest risk was with HPV-16 (21.1 [6.3-70.0], p < 0.0001). Similar findings were seen for infections of any duration. Significant risk was also observed for HPV-18, HPV-31, and HPV-45. Concomitant HPV infection or CIN grade 1 or greater associated with a different oncogenic HPV type increased risk. Most women (79.3%) with an HPV infection at baseline cleared detectable infections of any duration, and 69.9% cleared a 6MPI. The risk of progression of HPV infection to CIN2+ in women >25 years in this study was similar to that in women 15-25 years in PATRICIA.</AbstractText>
<CopyrightInformation>© 2015 The Authors and GlaxoSmithKline. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skinner</LastName>
<ForeName>S Rachel</ForeName>
<Initials>SR</Initials>
<AffiliationInfo><Affiliation>Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wheeler</LastName>
<ForeName>Cosette M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Romanowski</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castellsagué</LastName>
<ForeName>Xavier</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lazcano-Ponce</LastName>
<ForeName>Eduardo</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>National Institute of Public Health, Cuernavaca, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Del Rosario-Raymundo</LastName>
<ForeName>M Rowena</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vallejos</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Division de Investigacion Oncosalud-AUNA, Lima, Peru.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Minkina</LastName>
<ForeName>Galina</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>City Clinical Hospital, Moscow, Russian Federation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pereira Da Silva</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McNeil</LastName>
<ForeName>Shelly</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Canadian Center for Vaccinology, IWK Health Center and Capital Health, Dalhousie University, Halifax, NS, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prilepskaya</LastName>
<ForeName>Vera</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gogotadze</LastName>
<ForeName>Irina</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>City Medical Center, St Petersburg, Russian Federation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Money</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>University of British Columbia, The Women's Health Research Institute, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garland</LastName>
<ForeName>Suzanne M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Romanenko</LastName>
<ForeName>Viktor</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>City Children's Hospital N40, Ekaterinburg, Russian Federation.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harper</LastName>
<ForeName>Diane M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Geisel School of Medicine at Dartmouth, Hanover, NH, USA and University of Louisville School of Medicine, Louisville, KT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levin</LastName>
<ForeName>Myron J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chatterjee</LastName>
<ForeName>Archana</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Geeraerts</LastName>
<ForeName>Brecht</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Struyf</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dubin</LastName>
<ForeName>Gary</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, King of Prussia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bozonnat</LastName>
<ForeName>Marie-Cécile</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>4Clinics, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosillon</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baril</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>VIVIANE Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00294047</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Int J Cancer</MedlineTA>
<NlmUniqueID>0042124</NlmUniqueID>
<ISSNLinking>0020-7136</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053918">Papillomavirus Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1060-9</RefSource>
<PMID Version="1">19336546</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2010 Nov 1;70(21):8569-77</RefSource>
<PMID Version="1">20978200</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30</RefSource>
<PMID Version="1">19648510</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Feb 15;132(4):854-67</RefSource>
<PMID Version="1">22752992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2014;14:551</RefSource>
<PMID Version="1">25927224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2013 Aug 1;208(3):403-12</RefSource>
<PMID Version="1">23599313</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BJOG. 2001 Mar;108(3):295-303</RefSource>
<PMID Version="1">11281472</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2001 Jun 20;285(23):2995-3002</RefSource>
<PMID Version="1">11410098</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2001 Dec 15;184(12):1508-17</RefSource>
<PMID Version="1">11740725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2002 Feb 1;185(3):324-31</RefSource>
<PMID Version="1">11807714</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13</RefSource>
<PMID Version="1">12419786</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biometrics. 1986 Mar;42(1):121-30</RefSource>
<PMID Version="1">3719049</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1994 Feb;169(2):235-40</RefSource>
<PMID Version="1">8106758</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1996 Apr 6;347(9006):941-3</RefSource>
<PMID Version="1">8598759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2004 Dec 15;190(12):2077-87</RefSource>
<PMID Version="1">15551205</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2005 Jan 19;97(2):147-50</RefSource>
<PMID Version="1">15657345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Virology. 2005 Jun 20;337(1):76-84</RefSource>
<PMID Version="1">15914222</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2005 Nov 1;117(2):177-81</RefSource>
<PMID Version="1">15900579</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 Oct 1;192(7):1158-65</RefSource>
<PMID Version="1">16136457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2006 Mar 15;118(6):1481-95</RefSource>
<PMID Version="1">16206285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2006 Sep;44(9):3292-8</RefSource>
<PMID Version="1">16954263</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2007 Feb 15;120(4):885-91</RefSource>
<PMID Version="1">17131323</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2010 Dec 15;202(12):1789-99</RefSource>
<PMID Version="1">21067372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96</RefSource>
<PMID Version="1">21300618</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Apr 1;203(7):910-20</RefSource>
<PMID Version="1">21402543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Aug 1;204(3):385-90</RefSource>
<PMID Version="1">21742837</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2012 May;227(1):62-71</RefSource>
<PMID Version="1">22127961</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Jan 1;132(1):198-207</RefSource>
<PMID Version="1">22532127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2012 Dec;127(3):440-50</RefSource>
<PMID Version="1">22940493</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F88-99</RefSource>
<PMID Version="1">23199969</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2007 Feb 28;297(8):813-9</RefSource>
<PMID Version="1">17327523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Jun 30;369(9580):2161-70</RefSource>
<PMID Version="1">17602732</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2008 Feb 12;98(3):646-51</RefSource>
<PMID Version="1">18182990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Epidemiol. 2008 Jun;37(3):536-46</RefSource>
<PMID Version="1">18316350</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2008 Jul 15;168(2):123-37</RefSource>
<PMID Version="1">18483125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 Apr 1;101(7):475-87</RefSource>
<PMID Version="1">19318628</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Nov;11(11):1048-56</RefSource>
<PMID Version="1">20952254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(11):e79260</RefSource>
<PMID Version="1">24260180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2014 Mar;209(6):855-64</RefSource>
<PMID Version="1">24179110</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(2):e90023</RefSource>
<PMID Version="1">24587193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2014 May;60(1):44-9</RefSource>
<PMID Version="1">24630483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2014 Aug 15;210(4):517-34</RefSource>
<PMID Version="1">24610876</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Dec 20;384(9961):2213-27</RefSource>
<PMID Version="1">25189358</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2013;(3):CD008054</RefSource>
<PMID Version="1">23543559</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Decis Making. 2010 Jan-Feb;30(1):84-98</RefSource>
<PMID Version="1">19525483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2010 Jan;46(2):405-11</RefSource>
<PMID Version="1">19819687</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):503-10</RefSource>
<PMID Version="1">20142247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jun 6;373(9679):1949-57</RefSource>
<PMID Version="1">19493565</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D052685" MajorTopicYN="N">Alphapapillomavirus</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018290" MajorTopicYN="N">Cervical Intraepithelial Neoplasia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053918" MajorTopicYN="N">Papillomavirus Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D062486" MajorTopicYN="N">Public Health Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4787275</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CIN</Keyword>
<Keyword MajorTopicYN="N">HPV</Keyword>
<Keyword MajorTopicYN="N">VIVIANE</Keyword>
<Keyword MajorTopicYN="N">adult women</Keyword>
<Keyword MajorTopicYN="N">natural history</Keyword>
</KeywordList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>David</LastName>
<ForeName>Marie-Pierre</ForeName>
<Initials>MP</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Raillard</LastName>
<ForeName>Alice</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Souza</LastName>
<ForeName>Sabrina Collas</ForeName>
<Initials>SC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Le Plain</LastName>
<ForeName>Aurélie</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Descamps</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hardt</LastName>
<ForeName>Karin</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Greenacre</LastName>
<ForeName>Mary</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Delval</LastName>
<ForeName>Stéphanie</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Andersson</LastName>
<ForeName>Jenny</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Verheijen</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stapleton</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tay</LastName>
<ForeName>E H</ForeName>
<Initials>EH</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Quek</LastName>
<ForeName>S C</ForeName>
<Initials>SC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martens</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cruiskshank</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Girard</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bouchard</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fong</LastName>
<ForeName>K L</ForeName>
<Initials>KL</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ilancheran</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Patricio</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Julien</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stoney</LastName>
<ForeName>T M</ForeName>
<Initials>TM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ferguson</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cruz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gomez Moreno</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Savitcheva</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Savani</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chambers</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fine</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fox</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hedrick</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rosen</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sperling</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Angsuwathana</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tristram</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>ter Harmsel</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ferguson</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Poling</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ilina</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chakhtoura</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Utian</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hansen</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Leeman</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Szarewski</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>11</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>11</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>12</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>12</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26685704</ArticleId>
<ArticleId IdType="doi">10.1002/ijc.29971</ArticleId>
<ArticleId IdType="pmc">PMC4787275</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001E72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26685704 |texte= Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26685704" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |